Nexalin Technology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Nexalin Technology şirketinin toplam hissedar öz sermayesi $5.0M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $5.3M ve $299.4K dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$4.59m
Eşitlik	US$4.96m
Toplam yükümlülükler	US$299.39k
Toplam varlıklar	US$5.26m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: NXL 'nin kısa vadeli varlıkları ( $4.9M ) kısa vadeli yükümlülüklerini ( $299.4K ) aşıyor.

Uzun Vadeli Yükümlülükler: NXL un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: NXL borçsuzdur.

Borcun Azaltılması: NXL un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: NXL şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: NXL serbest nakit akışı her yıl % 40.4 1.2 yıl yetecek nakit akışına sahip olacaktır.

Nexalin Technology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Nexalin Technology Regains Compliance with Nasdaq’s Minimum Bid Price Requirement under Nasdaq Rule 5550(a)(2)

Nexalin Technology Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Nexalin Technology, Inc. Provides Non-Compliance Update

Nexalin Technology, Inc. Regains Compliance with Nasdaq Continued Listing Requirements

Nexalin Technology Receives Written Notice from the Nasdaq Listing Qualifications Department Regarding Not Eligible for an Additional 180 Calendar Day Compliance Period

Nexalin Technology, Inc. Receives Written Notice from the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Recent updates

New major risk - Shareholder dilution

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Nexalin Technology Regains Compliance with Nasdaq’s Minimum Bid Price Requirement under Nasdaq Rule 5550(a)(2)

New major risk - Revenue and earnings growth

Nexalin Technology Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Second quarter 2024 earnings released: US$0.17 loss per share (vs US$0.11 loss in 2Q 2023)

New major risk - Market cap size

Nexalin Technology, Inc., Annual General Meeting, Aug 26, 2024

Nexalin Technology, Inc. has completed a Follow-on Equity Offering in the amount of $5.25 million.

Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal

Nexalin Technology, Inc. Announces FDA Provides Feedback and Reaches Consensus on Nexalin's Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 Halo Clarity Headset Device

Nexalin Technology, Inc. has filed a Follow-on Equity Offering in the amount of $7 million.

Nexalin Technology, Inc. Provides Non-Compliance Update

First quarter 2024 earnings released: US$0.14 loss per share (vs US$0.10 loss in 1Q 2023)

Nexalin Technology, Inc. Regains Compliance with Nasdaq Continued Listing Requirements

Nexalin Technology, Inc. has filed a Follow-on Equity Offering in the amount of $5.646485 million.

Nexalin Technology Accelerates Manufacturing of Its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing

Nexalin Technology, Inc. Announces the Appointment of William A. Hudson, Jr. to Military & Government Advisory Board

Full year 2023 earnings released: US$0.63 loss per share (vs US$0.30 loss in FY 2022)

Nexalin Technology, Inc. Announces Positive Results of Clinical Study Validating its Gen-2 TACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego

Nexalin Technology, Inc. Announces Positive Results from Clinical Study of Its Gen-2 Tacs Device for Treating Adult Patients with Chronic Insomnia

Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device

Nexalin Technology, Inc. Unveils Gen-3 HALO™? Clarity 15 Milliamp Neurostimulation Device

Third quarter 2023 earnings released: US$0.31 loss per share (vs US$0.026 loss in 3Q 2022)

Nexalin Technology Receives Written Notice from the Nasdaq Listing Qualifications Department Regarding Not Eligible for an Additional 180 Calendar Day Compliance Period

Nexalin Technology, Inc. Announces Publication of Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal

Nexalin Technology, Inc., Annual General Meeting, Nov 10, 2023

Nexalin Technology, Inc., Annual General Meeting, Nov 10, 2023

Second quarter 2023 earnings released: US$0.11 loss per share (vs US$0.09 loss in 2Q 2022)

Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of Its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms

Nexalin Technology, Inc. Receives Written Notice from the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

First quarter 2023 earnings released: US$0.10 loss per share (vs US$0.08 loss in 1Q 2022)

Full year 2022 earnings released: US$0.30 loss per share (vs US$1.43 loss in FY 2021)

Nexalin Technology, Inc. Appoints Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory

Insufficient new directors

Third quarter 2022 earnings released: US$0.026 loss per share (vs US$0.40 loss in 3Q 2021)

Nexalin Technology, Inc. has completed an IPO in the amount of $9.60725 million.

Nexalin Technology, Inc. has completed an IPO in the amount of $9.60725 million.

Nexalin Technology, Inc. has completed an IPO in the amount of $9.60725 million.

Insufficient new directors

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin